Objectives-To determine the prevalence of antibodies to the human T cell leukaemia/lymphoma viruses (HTLV-I and HTLV-II) in blood donors in north London in order to assess the economic impact and the logistic effects that routine screening would have on the blood supply.
Introduction
Although several infectious diseases are transmissible by blood transfusion, HIV has been the main focus of public and scientific concern over the past 10 years. Education of donors and self exclusion, careful selection of donors, screening of blood donations, and procedures for inactivation of viruses in blood products have now become routine in developed countries. Despite these effective measures there is still considerable public anxiety about the safety of blood and its derivatives. The known existence of other human viruses with a potential for transmission by transfusion has exacerbated this anxiety. The human T-cell leukaemia/lymphoma virus type I (HTLV-I) is one of these viruses, as is the closely related human T cell leukaemia/lymphoma virus type II (HTLV-II). ' In 1980 HTLV-I, the first human retrovirus to be described, was identified. It is endemic in Japan, the Caribbean, the south eastern United States, and parts of Africa. Seroprevalence varies between and within endemic areas. As many as 15% of the population in some areas of southwest Japan have antibodies to HTLV in their serum, and seroprevalence in the Caribbean is reported to be between 1% and 4%. Although the seroprevalence in non-endemic areas is low, infections with HTLV-I have been identified in immigrants from endemic areas. 2 HTLV-I is transmitted and maintained in the population by sexual intercourse, breast feeding, misuse of intravenous drugs, and, less commonly, by blood transfusion. 3 The epidemiology of HTLV-II is less certain but is probably similar. In areas of low endemicity infection with both HTLV-I and HTLV-II has been associated with blood transfusion4 and parenteral drug use.' HTLV-I is an intracellular virus; it is transmitted by both whole blood and cellular blood components but rarely by fresh plasma and not at all by plasma products.6 Rates of seroconversion of between 50% and 80% have been recorded in recipients of seropositive whole blood, red cell concentrates, and platelets. Transmission is more likely if blood components are fresh.7
It is now established that HTLV-I is associated with at least two diseases: an aggressive malignancy (adult T cell leukaemia/lymphoma) and a chronic neurological disorder (tropical spastic paraparesis, also called HTLV associated myelopathy). Adult Routine screening of all blood donations for HTLV antibodies was introduced in the United States in late 1988 and shortly thereafter in Canada. During the first nine months of testing in the United States the seroprevalence was approximately 0-017% (C T Fang, A E Williams, S G Sandler, third annual retrovirology conference, Hawaii, 1990) . Most (52%) seropositive donors in the United States are confirmed to be positive for antibodies to HTLV-II.'5 In France, however, where routine screening was introduced in 1991, the seroprevalence is lower (0 004%), and only 1-5% of seropositive donors have HTLV-II infection. '6 A small survey of the seroprevalence of HTLV performed at the North London Blood Transfusion Centre in 1989 detected no confirmed positive samples in 5000 unselected samples from donors. On the other hand, serum samples from two out of 2376 AfroCaribbean donors at the centre were confirmed to be positive for HTLV antibodies.'7 Before deciding whether to introduce routine screening of donors in the United Kingdom it would be important to know the overall prevalence of HTLV antibodies. The economic impact and the logistical effects that screening would have on the blood supply could also then be ascertained.
Methods
Between 2 January and 30 June 1991 all blood and plasma donations collected by the transfusion centre were screened for HTLV antibodies by a modification of the gelatin particle agglutination test by using improved reagents from the manufacturer (Fujirebio, Japan). '8 '9 Provided that all the usual selection criteria for donors were 
Discussion
The prevalence of antibodies to HTLV in blood donors in north London is about one in 20 000 compared with a rate of one in 6000 in North American blood donors. '5 This implies that if routine screening for HTLV antibodies were introduced in the United Kingdom up to 100 donors might be expected to be confirmed positive for HTLV in the first year of screening. In reality the prevalence of these antibodies in the rest of the country may well be lower, paralleling the results in France, where an identical seroprevalence of antibodies to HTLV was found but restricted to metropolitan areas. 23 Our large scale study has shown that it would be difficult to specify groups for selective donor screening. Selective screening for HTLV antibodies based on ethnic origin would have detected only one of the five confirmed donors, a 31 year old Anglo-Caribbean man. Moreover, his ethnic origin did not prove predictive of HTLV-I infection, as he was shown to be infected with HTLV-II, presumably associated with his history of misuse of intravenous drugs. He was also a carrier of hepatitis C virus and had previously been infected with hepatitis B virus. He had not admitted to misuse of intravenous drugs in the confidential questionnaire completed by all donors at the transfusion centre.
Two infected donors (1 and 3) would have been preselected for screening only if a detailed sexual history had been obtained. Donor Our observed prevalence of antibodies to HTLV of one in 20 000 is a much lower carrier rate than that for hepatitis B and C viruses (about one in 1500 new donors) but is similar to that of antibodies to HIV-1 and HIV-2 in new donors (one in 23 000). Morbidity in HTLV infection, however, is far less common than in HIV infection (< 5% v > 50% lifetime risk).
Studies on the rate of HTLV-I infection in recipients receiving infected blood have shown that up to 70% of recipients of cellular blood components will seroconvert. In addition, the number of days that blood is stored before transfusion is inversely related to the proportion of seroconversions in recipients. In one study 79-2% of recipients of blood stored for 1-5 days seroconverted, compared with 63-6% and BMJ VOLUME 307 13 NOVEMBER 1993 55% after storage for 6-10 and 11-16 days, respectively.' Relatively few cases of HTLV-I disease associated with transfusion have been reported and these have nearly all been cases of tropical spastic paraparesis. The usually protracted incubation period between infection with HTLV-I and onset of symptoms makes it difficult to establish a causal relation with transfusion, but there have also been reports of accelerated development of tropical spastic paraparesis in recipients of infected blood components after short intervals: 18 weeks in one case and six months in another.8 It has been estimated that for HTLV-I seropositive subjects the lifetime risks of adult T cell leukaemia/lymphoma and of tropical spastic paraparesis are in the order of 2-4%2 and 0 25%," respectively. Given that the NHS has limited financial resources it is essential to attempt a cost-benefit analysis of the impact of routine screening for HTLV antibodies. In the United Kingdom, if up to 100 donors positive for anti-HTLV give blood in one year, a maximum of 200 cellular components positive for anti-HTLV could potentially be transfused each year (though probably some 10% would not be transfused). If about 70% of recipients seroconverted for HTLV antibodies there would be 140 infections arising from transfusion annually in the United Kingdom. Since the combined lifetime risk of adult T cell leukaemia/lymphoma and tropical spastic paraparesis is probably less than 5%, every year up to six people may be put at risk of developing HTLV associated disease in their lifetime. In practice fewer are at risk as half the blood is transfused into patients who die within one year. Thus if routine screening of all donations for antibodies were introduced the direct impact on disease prevention would be very small, although secondary infections in the sexual partners or breast fed infants of infected donors and recipients of transfusions would also be preventable.
COSTS OF SCREENING
Reagent costs for routine testing for anti-HTLV in the United Kingdom with currently available ELISAs would be in the region of C2m a year. Confirmatory testing would be required for between 0X2% and 0 3% of donations, and these would be unavailable for transfusion. The minimum cost of preventing a single transmission related to transfusion is about £30 000 and for preventing the risk of HTLV associated disease developing in a recipient's lifetime, C1 3m. We acknowledge that in the absence of more clinical data to predict the illness caused by HTLV infection in a Westem population these are tentative projections but even so they provide some idea of the impact of screening.
Counselling of donors positive for HTLV was not straightforward. The concept of a latent virus that will probably be inapparent throughout the person's life had to be explained. Its transmissibility to children and sexual partners and the small risk for the development of acute leukaemia or paralysis also had to be discussed. It was helpful to be able to refer positive donors to a clinical specialist with an interest in retrovirus infections since most general practitioners in the United Kingdom have little experience of HTLV infection.
In the light of these results can we justify screening for HTLV? If not, can we defend a decision not to screen in the face of the Consumer Protection Act and product liability? The fact that routine screening for HTLV is occurring in the United States, Japan, and some European countries is bound to have a bearing on practice in Europe and on the decision in the United Kingdom.
Finally, if routine screening were to be introduced there would be the options of using an assay for HTLV-I and HTLV-II antibodies or a combined Twins born in Western Australia in 1991 were four times more likely than singletons to be stillborn and five times more likely to die as neonates.7 Twins were 16 times more likely than singletons to weigh less than 1500 g at birth; one in 3-3 liveborn infants weighing under 1500 g was from a multiple birth. Twins required neonatal intensive care eight times more often than singletons, 21 times more often for longer than 28 days. Comparable figures for triplets are not available in Western Australia but probably the risks and stresses for triplet births are even greater. The problems experienced by parents and medical staff and the costs resulting from the increase in multiple births have been discussed in the lay68 and medical press.2 9 10 In addition to their vulnerability to early illness and death,"' twins are at higher risk of developing cerebral palsy.'213 A previous population based report from Western Australia describing births from 1956 to 1985 observed a prevalence of cerebral palsy in twins 2-6 times that in singletons and found suggestive but, because of small numbers, inconclusive evidence that triplets were at higher risk of cerebral palsy than twins.'4 We now update that earlier report and further examine the risk of cerebal palsy or of death in multiple births in this population in the decade of the 1980s.
Methods
Plurality and annual numbers of births and their characteristics including birth weight for the years 1980 to 1989 were obtained from the maternal and child health research database, which includes midwives' notifications of births (a statutory file of all births in the state collected by the health department of Western Australia including stillbirths of at least 20 weeks' gestation or 400 g birth weight), and linked to birth registrations and deaths to the age of 1 year provided by the registrar general of Western Australia. Population data for years before 1980 were obtained from publications of the Australian Bureau of Statistics'5 and the health department of Western Australia.'6 1 ' Details of cases of cerebral palsy were obtained from the Western Australian cerebral palsy register, an ongoing population based system that uses multiple
